Qiagen (NASDAQ: QGEN) reported Q4 EPS of $0.43, $0.02 better than the analyst estimate of $0.41. Revenue for the quarter came in at $396.6 million versus the consensus estimate of $393.33 million.

• Solid Q4 results as QIAGEN achieves full-year 2017 targets:
• Q4 2017: Net sales $396.9 million (+8% actual, +5% CER); adjusted net sales rise 6% CER excluding portfolio changes vs. 5-6% CER guidance
• Q4 2017: EPS -$0.18 including impact of predominantly non-cash U.S. tax reform charge; adjusted EPS $0.43 ($0.43 CER) vs. ~$0.41-42 CER guidance
• Full-year 2017: Achieved guidance with 7% CER adjusted net sales growth excluding portfolio changes and adjusted diluted EPS of $1.27 CER
• Full-year 2017: Adjusted operating income margin improves to 26% of adjusted sales from 24% in 2016
• New $200 million share repurchase commitment through open-market repurchase
• Acquisition of STAT-Dx adds QIAstat-Dx, a next-generation PCR-based multiplex syndromic testing solution with expected European launch in second half of 2018
• QIAGEN sets 2018 outlook for further growth in adjusted net sales and adjusted EPS, reaffirms 2020 mid-term targets for improving performance

For earnings history and earnings-related data on Qiagen (QGEN) click here.